Effect of bromocryptine in oligozoospermic men with hyperprolactinaemia

Area of Science:

• Reproductive Endocrinology
• Andrology
• Pharmacology

Background:

• Oligozoospermia is a common cause of male infertility.
• Elevated serum prolactin levels can negatively impact spermatogenesis.
• Prolactinomas are pituitary tumors causing high prolactin, but other causes exist.

Purpose of the Study:

• To investigate the effect of bromocriptine, a prolactin inhibitor, on sperm parameters in men with oligozoospermia and hyperprolactinemia without a prolactinoma.
• To assess the impact of reducing prolactin on semen quality.

Main Methods:

• A cohort of 13 male patients with oligozoospermia and elevated serum prolactin (without prolactinoma) were treated with bromocriptine.
• Treatment duration was 50 days.
• Semen parameters and serum prolactin levels were analyzed before and after treatment.

Main Results:

• Serum prolactin levels were significantly reduced in all patients.
• Sperm count increased in 6 patients, decreased in 2, and remained unchanged in 5.
• Other semen parameters, such as sperm motility and morphology, showed no significant alterations.

Conclusions:

• Bromocriptine effectively lowers serum prolactin in men with oligozoospermia and hyperprolactinemia.
• The effect of prolactin inhibition on spermatogenesis is variable and not fully understood.
• The therapeutic value of bromocriptine for improving sperm count in this specific patient group remains uncertain.